Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drugs

Open Access 17-04-2024 | Idiopathic Pulmonary Fibrosis | Leading Article

Sirtuins and Cellular Senescence in Patients with Idiopathic Pulmonary Fibrosis and Systemic Autoimmune Disorders

Authors: Vito D’Agnano, Domenica Francesca Mariniello, Raffaella Pagliaro, Mehrdad Savabi Far, Angela Schiattarella, Filippo Scialò, Giulia Stella, Maria Gabriella Matera, Mario Cazzola, Andrea Bianco, Fabio Perrotta

Published in: Drugs

Login to get access

Abstract

The sirtuin family is a heterogeneous group of proteins that play a critical role in many cellular activities. Several degenerative diseases have recently been linked to aberrant sirtuin expression and activity because of the involvement of sirtuins in maintaining cell longevity and their putative antiaging function. Idiopathic pulmonary fibrosis and progressive pulmonary fibrosis associated with systemic autoimmune disorders are severe diseases characterized by premature and accelerated exhaustion and failure of alveolar type II cells combined with aberrant activation of fibroblast proliferative pathways leading to dramatic destruction of lung architecture. The mechanisms underlying alveolar type II cell exhaustion in these disorders are not fully understood. In this review, we have focused on the role of sirtuins in the pathogenesis of idiopathic and secondary pulmonary fibrosis and their potential as biomarkers in the diagnosis and management of fibrotic interstitial lung diseases.
Literature
1.
Moss BJ, Ryter SW, Rosas IO. Pathogenic mechanisms underlying idiopathic pulmonary fibrosis. Annu Rev Pathol Mech Dis. 2021;17:515–46.CrossRef
2.
Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, Behr J, Cottin V, Danoff SK, Morell F, et al. Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2018;198:e44–68.PubMedCrossRef
3.
Herzog EL, Mathur A, Tager AM, Feghali-Bostwick C, Schneider F, Varga J. Review: interstitial lung disease associated with systemic sclerosis and idiopathic pulmonary fibrosis: how similar and distinct? Arthritis Rheumatol (Hoboken, NJ). 2014;66:1967–78.CrossRef
4.
Hambly N, Farooqi MM, Dvorkin-Gheva A, Donohoe K, Garlick K, Scallan C, Chong SG, MacIsaac S, Assayag D, Johannson KA, et al. Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registry. Eur Respir J. 2022;60:2102571.PubMedCrossRef
5.
D’Agnano V, Mariniello DF, Ruotolo M, Quarcio G, Moriello A, Conte S, Sorrentino A, Sanduzzi Zamparelli S, Bianco A, Perrotta F. Targeting progression in pulmonary fibrosis: an overview of underlying mechanisms, molecular biomarkers, and therapeutic intervention. Life. 2024;14:229.PubMedPubMedCentralCrossRef
6.
Rubio-Rivas M, Royo C, Simeón CP, Corbella X, Fonollosa V. Mortality and survival in systemic sclerosis: systematic review and meta-analysis. Semin Arthritis Rheum. 2014;44:208–19.PubMedCrossRef
7.
8.
Todd NW, Luzina IG, Atamas SP. Molecular and cellular mechanisms of pulmonary fibrosis. Fibrogen Tissue Repair. 2012;5:11.CrossRef
9.
10.
Parimon T, Yao C, Stripp BR, Noble PW, Chen P. Alveolar epithelial type II cells as drivers of lung fibrosis in idiopathic pulmonary fibrosis. Int J Mol Sci. 2020;21:2269.PubMedPubMedCentralCrossRef
11.
Mazumder S, Barman M, Bandyopadhyay U, Bindu S. Sirtuins as endogenous regulators of lung fibrosis: a current perspective. Life Sci. 2020;258: 118201.PubMedCrossRef
12.
Perrotta F, Chino V, Allocca V, D’Agnano V, Bortolotto C, Bianco A, Corsico AG, Stella GM. Idiopathic pulmonary fibrosis and lung cancer: targeting the complexity of the pharmacological interconnection. Expert Rev Respir Med. 2022;16:1043–55.PubMedCrossRef
13.
Stella GM, D’Agnano V, Piloni D, Saracino L, Lettieri S, Mariani F, Lancia A, Bortolotto C, Rinaldi P, Falanga F, et al. The oncogenic landscape of the idiopathic pulmonary fibrosis: a narrative review. Transl Lung Cancer Res. 2022;11:472–96.PubMedPubMedCentralCrossRef
14.
Ji Z, Liu G-H, Qu J. Mitochondrial sirtuins, metabolism, and aging. J Genet Genom. 2022;49:287–98.CrossRef
15.
Aventaggiato M, Barreca F, Sansone L, Pellegrini L, Russo MA, Cordani M, Tafani M. Sirtuins and hypoxia in EMT control. Pharmaceuticals (Basel). 2022;15:737.PubMedCrossRef
16.
Corbi G, Bianco A, Turchiarelli V, Cellurale M, Fatica F, Daniele A, Mazzarella G, Ferrara N. Potential mechanisms linking atherosclerosis and increased cardiovascular risk in COPD: focus on Sirtuins. Int J Mol Sci. 2013;14:12696–713.PubMedPubMedCentralCrossRef
17.
Michan S, Sinclair D. Sirtuins in mammals: insights into their biological function. Biochem J. 2007;404:1–13.PubMedCrossRef
18.
Zhang N, Li Z, Mu W, Li L, Liang Y, Lu M, Wang Z, Qiu Y, Wang Z. Calorie restriction-induced SIRT6 activation delays aging by suppressing NF-κB signaling. Cell Cycle. 2016;15:1009–18.PubMedPubMedCentralCrossRef
19.
Du J, Zhou Y, Su X, Yu JJ, Khan S, Jiang H, Kim J, Woo J, Kim JH, Choi BH, et al. Sirt5 is a NAD-dependent protein lysine demalonylase and desuccinylase. Science. 2011;334:806–9.PubMedPubMedCentralCrossRef
20.
Scher MB, Vaquero A, Reinberg D. SirT3 is a nuclear NAD+-dependent histone deacetylase that translocates to the mitochondria upon cellular stress. Genes Dev. 2007;21:920–8.PubMedPubMedCentralCrossRef
21.
Bindu S, Pillai VB, Gupta MP. Role of sirtuins in regulating pathophysiology of the heart. Trends Endocrinol Metab. 2016;27:563–73.PubMedCrossRef
22.
23.
Inoue T, Hiratsuka M, Osaki M, Yamada H, Kishimoto I, Yamaguchi S, Nakano S, Katoh M, Ito H, Oshimura M. SIRT2, a tubulin deacetylase, acts to block the entry to chromosome condensation in response to mitotic stress. Oncogene. 2007;26:945–57.PubMedCrossRef
24.
Michishita E, Park JY, Burneskis JM, Barrett JC, Horikawa I. Evolutionarily conserved and nonconserved cellular localizations and functions of human SIRT proteins. Mol Biol Cell. 2005;16:4623–35.PubMedPubMedCentralCrossRef
25.
Königshoff M, Balsara N, Pfaff E-M, Kramer M, Chrobak I, Seeger W, Eickelberg O. Functional Wnt signaling is increased in idiopathic pulmonary fibrosis. PLoS ONE. 2008;3: e2142.PubMedPubMedCentralCrossRef
26.
Tian Y, Li H, Qiu T, Dai J, Zhang Y, Chen J, Cai H. Loss of PTEN induces lung fibrosis via alveolar epithelial cell senescence depending on NF-κB activation. Aging Cell. 2019;18: e12858.PubMedCrossRef
27.
Kawahara TLA, Michishita E, Adler AS, Damian M, Berber E, Lin M, McCord RA, Ongaigui KCL, Boxer LD, Chang HY, et al. SIRT6 links histone H3 lysine 9 deacetylation to NF-kappaB-dependent gene expression and organismal life span. Cell. 2009;136:62–74.PubMedPubMedCentralCrossRef
28.
Tian K, Chen P, Liu Z, Si S, Zhang Q, Mou Y, Han L, Wang Q, Zhou X. Sirtuin 6 inhibits epithelial to mesenchymal transition during idiopathic pulmonary fibrosis via inactivating TGF-β1/Smad3 signaling. Oncotarget. 2017;8:61011–24.PubMedPubMedCentralCrossRef
29.
Wang F, Marshall CB, Ikura M. Forkhead followed by disordered tail: the intrinsically disordered regions of FOXO3a. Intrinsical Disord Proteins. 2015;3: e1056906.CrossRef
30.
Giannakou ME, Partridge L. The interaction between FOXO and SIRT1: tipping the balance towards survival. Trends Cell Biol. 2004;14:408–12.PubMedCrossRef
31.
Luo J, Nikolaev AY, Imai S, Chen D, Su F, Shiloh A, Guarente L, Gu W. Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell. 2001;107:137–48.PubMedCrossRef
32.
Sehgal M, Jakhete SM, Manekar AG, Sasikumar S. Specific epigenetic regulators serve as potential therapeutic targets in idiopathic pulmonary fibrosis. Heliyon. 2022;8: e09773.PubMedPubMedCentralCrossRef
33.
Ming Y, Yin Y, Sun Z. Interaction of nuclear receptor subfamily 4 group a member 1 (Nr4a1) and liver linase B1 (LKB1) mitigates type 2 diabetes mellitus by activating monophosphate-activated protein kinase (AMPK)/Sirtuin 1 (SIRT1) axis and inhibiting nuclear factor-kappa B. Med Sci Monit Int Med J Exp Clin Res. 2020;26: e920278.
34.
Deskata K, Malli F, Jagirdar R, Vavougios GD, Zarogiannis S, Gourgoulianis KI, Daniil Z. Evaluation of Sirtuin 1 levels in peripheral blood mononuclear cells of patients with idiopathic pulmonary fibrosis. Cureus. 2022;14: e30862.PubMedPubMedCentral
35.
Zeng Z, Cheng S, Chen H, Li Q, Hu Y, Wang Q, Zhu X, Wang J. Activation and overexpression of Sirt1 attenuates lung fibrosis via P300. Biochem Biophys Res Commun. 2017;486:1021–6.PubMedCrossRef
36.
37.
Liang J, Huang G, Liu X, Taghavifar F, Liu N, Wang Y, Deng N, Yao C, Xie T, Kulur V, et al. The ZIP8/SIRT1 axis regulates alveolar progenitor cell renewal in aging and idiopathic pulmonary fibrosis. J Clin Invest. 2022;132: e157338.PubMedPubMedCentralCrossRef
38.
Lambona C, Zwergel C, Valente S, Mai A. SIRT3 Activation a promise in drug development? New insights into SIRT3 biology and its implications on the drug discovery process. J Med Chem. 2024;67:1662–89.PubMedPubMedCentralCrossRef
39.
Amara N, Goven D, Prost F, Muloway R, Crestani B, Boczkowski J. NOX4/NADPH oxidase expression is increased in pulmonary fibroblasts from patients with idiopathic pulmonary fibrosis and mediates TGF-β1-induced fibroblast differentiation into myofibroblasts. Thorax. 2010;65:733–8.PubMedCrossRef
40.
Hecker L, Vittal R, Jones T, Jagirdar R, Luckhardt TR, Horowitz JC, Pennathur S, Martinez FJ, Thannickal VJ. NADPH oxidase-4 mediates myofibroblast activation and fibrogenic responses to lung injury. Nat Med. 2009;15:1077–81.PubMedPubMedCentralCrossRef
41.
Cheresh P, Kim S-J, Jablonski R, Watanabe S, Lu Z, Chi M, Helmin KA, Gius D, Budinger GRS, Kamp DW. SIRT3 Overexpression ameliorates asbestos-induced pulmonary fibrosis, mt-DNA damage, and lung fibrogenic monocyte recruitment. Int J Mol Sci. 2021;22:6856.PubMedPubMedCentralCrossRef
42.
Guo W, Saito S, Sanchez CG, Zhuang Y, Gongora Rosero RE, Shan B, Luo F, Lasky JA. TGF-β1 stimulates HDAC4 nucleus-to-cytoplasm translocation and NADPH oxidase 4-derived reactive oxygen species in normal human lung fibroblasts. Am J Physiol Lung Cell Mol Physiol. 2017;312:L936–44.PubMedPubMedCentralCrossRef
43.
Jablonski RP, Kim S-J, Cheresh P, Williams DB, Morales-Nebreda L, Cheng Y, Yeldandi A, Bhorade S, Pardo A, Selman M, et al. SIRT3 deficiency promotes lung fibrosis by augmenting alveolar epithelial cell mitochondrial DNA damage and apoptosis. FASEB J. 2017;31:2520–32.PubMedPubMedCentralCrossRef
44.
Rehan M, Kurundkar D, Kurundkar AR, Logsdon NJ, Smith SR, Chanda D, Bernard K, Sanders YY, Deshane JS, Dsouza KG, et al. Restoration of SIRT3 gene expression by airway delivery resolves age-associated persistent lung fibrosis in mice. Nat Aging. 2021;1:205–17.PubMedPubMedCentralCrossRef
45.
Sundaresan NR, Bindu S, Pillai VB, Samant S, Pan Y, Huang J-Y, Gupta M, Nagalingam RS, Wolfgeher D, Verdin E, et al. SIRT3 blocks aging-associated tissue fibrosis in mice by deacetylating and activating glycogen synthase kinase 3β. Mol Cell Biol. 2015;36:678–92.PubMedCrossRef
46.
47.
Sosulski ML, Gongora R, Feghali-Bostwick C, Lasky JA, Sanchez CG. Sirtuin 3 deregulation promotes pulmonary fibrosis. J Gerontol A Biol Sci Med Sci. 2017;72:595–602.PubMed
48.
Sundaresan NR, Vasudevan P, Zhong L, Kim G, Samant S, Parekh V, Pillai VB, Ravindra PV, Gupta M, Jeevanandam V, et al. The sirtuin SIRT6 blocks IGF-Akt signaling and development of cardiac hypertrophy by targeting c-Jun. Nat Med. 2012;18:1643–50.PubMedPubMedCentralCrossRef
49.
Cai J, Liu Z, Huang X, Shu S, Hu X, Zheng M, Tang C, Liu Y, Chen G, Sun L, et al. The deacetylase sirtuin 6 protects against kidney fibrosis by epigenetically blocking β-catenin target gene expression. Kidney Int. 2020;97:106–18.PubMedCrossRef
50.
Minagawa S, Araya J, Numata T, Nojiri S, Hara H, Yumino Y, Kawaishi M, Odaka M, Morikawa T, Nishimura SL, et al. Accelerated epithelial cell senescence in IPF and the inhibitory role of SIRT6 in TGF-β-induced senescence of human bronchial epithelial cells. Am J Physiol Lung Cell Mol Physiol. 2011;300:L391-401.PubMedCrossRef
51.
Kanwal A, Pillai VB, Samant S, Gupta M, Gupta MP. The nuclear and mitochondrial sirtuins, Sirt6 and Sirt3, regulate each other’s activity and protect the heart from developing obesity-mediated diabetic cardiomyopathy. FASEB J Off Publ Fed Am Soc Exp Biol. 2019;33:10872–88.
52.
Gauldie J, Kolb M, Ask K, Martin G, Bonniaud P, Warburton D. Smad3 signaling involved in pulmonary fibrosis and emphysema. Proc Am Thorac Soc. 2006;3:696–702.PubMedPubMedCentralCrossRef
53.
Wyman AE, Noor Z, Fishelevich R, Lockatell V, Shah NG, Todd NW, Atamas SP. Sirtuin 7 is decreased in pulmonary fibrosis and regulates the fibrotic phenotype of lung fibroblasts. Am J Physiol Cell Mol Physiol. 2017;312:L945–58.CrossRef
54.
Shaikh SB, Prabhu A, Bhandary YP. Targeting anti-aging protein sirtuin (Sirt) in the diagnosis of idiopathic pulmonary fibrosis. J Cell Biochem. 2019;120:6878–85.PubMedCrossRef
55.
Shen P, Deng X, Chen Z, Ba X, Qin K, Huang Y, Huang Y, Li T, Yan J, Tu S. SIRT1: a potential therapeutic target in autoimmune diseases. Front Immunol. 2021;12: 779177.PubMedPubMedCentralCrossRef
56.
57.
Cutolo M, Soldano S, Smith V. Pathophysiology of systemic sclerosis: current understanding and new insights. Expert Rev Clin Immunol. 2019;15:753–64.PubMedCrossRef
58.
59.
Wei J, Ghosh AK, Chu H, Fang F, Hinchcliff ME, Wang J, Marangoni RG, Varga J. The histone deacetylase sirtuin 1 is reduced in systemic sclerosis and abrogates fibrotic responses by targeting transforming growth factor β signaling. Arthritis Rheumatol (Hoboken, NJ). 2015;67:1323–34.CrossRef
60.
Chu H, Jiang S, Liu Q, Ma Y, Zhu X, Liang M, Shi X, Ding W, Zhou X, Zou H, et al. Sirtuin1 protects against systemic sclerosis-related pulmonary fibrosis by decreasing proinflammatory and profibrotic processes. Am J Respir Cell Mol Biol. 2018;58:28–39.PubMedPubMedCentralCrossRef
61.
Akamata K, Wei J, Bhattacharyya M, Cheresh P, Bonner MY, Arbiser JL, Raparia K, Gupta MP, Kamp DW, Varga J. SIRT3 is attenuated in systemic sclerosis skin and lungs, and its pharmacologic activation mitigates organ fibrosis. Oncotarget. 2016;7:69321–36.PubMedPubMedCentralCrossRef
62.
63.
Manetti M, Rosa I, Fioretto BS, Matucci-Cerinic M, Romano E. Decreased serum levels of SIRT1 and SIRT3 correlate with severity of skin and lung fibrosis and peripheral microvasculopathy in systemic sclerosis. J Clin Med. 2022;11:1362.PubMedPubMedCentralCrossRef
64.
Aletaha D, Smolen JS. Diagnosis and management of rheumatoid arthritis: a review. JAMA. 2018;320:1360–72.PubMedCrossRef
65.
66.
Li X, Li X, Zeng T, Liu Y, Hu T, Huang J, Wu Y, Yu J, Pei Z, Tan L. The clinical value of serum sirtuin-1 in the diagnosis of rheumatoid arthritis: a pilot study. Br J Biomed Sci. 2021;78:191–4.PubMedCrossRef
67.
Li G, Xia Z, Liu Y, Meng F, Wu X, Fang Y, Zhang C, Liu D. SIRT1 inhibits rheumatoid arthritis fibroblast-like synoviocyte aggressiveness and inflammatory response via suppressing NF-κB pathway. Biosci Rep. 2018;38:BSR20180541.PubMedPubMedCentralCrossRef
68.
Park SY, Lee SW, Kim HY, Lee SY, Lee WS, Hong KW, Kim CD. SIRT1 inhibits differentiation of monocytes to macrophages: amelioration of synovial inflammation in rheumatoid arthritis. J Mol Med (Berl). 2016;94:921–31.PubMedCrossRef
69.
70.
Deng Z, Wang Z, Jin J, Wang Y, Bao N, Gao Q, Zhao J. SIRT1 protects osteoblasts against particle-induced inflammatory responses and apoptosis in aseptic prosthesis loosening. Acta Biomater. 2017;49:541–54.PubMedCrossRef
71.
Zhang N, Zhang H, Law BYK, Dias IRDSR, Qiu CL, Zeng W, Dan Pan H, Chen JY, Bai YF, Lv J, et al. Sirtuin 5 deficiency increases disease severity in rats with adjuvant-induced arthritis. Cell Mol Immunol. 2020;17:1190–2.PubMedPubMedCentralCrossRef
72.
Hussain MZ, Haris MS, Khan MS, Mahjabeen I. Role of mitochondrial sirtuins in rheumatoid arthritis. Biochem Biophys Res Commun. 2021;584:60–5.PubMedCrossRef
73.
Kadura S, Raghu G. Rheumatoid arthritis-interstitial lung disease: manifestations and current concepts in pathogenesis and management. Eur Respir Rev. 2021;30: 210011.PubMedPubMedCentralCrossRef
74.
Ameer MA, Chaudhry H, Mushtaq J, Khan OS, Babar M, Hashim T, Zeb S, Tariq MA, Patlolla SR, Ali J, et al. An overview of systemic lupus erythematosus (SLE) pathogenesis, classification, and management. Cureus. 2022;14: e30330.PubMedPubMedCentral
75.
76.
Fortuny L, Sebastián C. Sirtuins as metabolic regulators of immune cells phenotype and function. Genes (Basel). 2021;12:1698.PubMedCrossRef
77.
Hisada R, Yoshida N, Umeda M, Burbano C, Bhargava R, Scherlinger M, Kono M, Kyttaris VC, Krishfield S, Tsokos GC. The deacetylase SIRT2 contributes to autoimmune disease pathogenesis by modulating IL-17A and IL-2 transcription. Cell Mol Immunol. 2022;19:738–50.PubMedPubMedCentralCrossRef
78.
Olivares D, Perez-Hernandez J, Forner MJ, Perez-Soriano C, Tormos MC, Saez GT, Chaves FJ, Redon J, Cortes R. Urinary levels of sirtuin-1 associated with disease activity in lupus nephritis. Clin Sci (Lond). 2018;132:569–79.PubMedCrossRef
79.
Yang C, Li R, Xu W-D, Huang A-F. Increased levels of sirtuin-1 in systemic lupus erythematosus. Int J Rheum Dis. 2022;25:869–76.PubMedCrossRef
80.
Sequeira J, Boily G, Bazinet S, Saliba S, He X, Jardine K, Kennedy C, Staines W, Rousseaux C, Mueller R, et al. sirt1-null mice develop an autoimmune-like condition. Exp Cell Res. 2008;314:3069–74.PubMedCrossRef
81.
Gan H, Shen T, Chupp DP, Taylor JR, Sanchez HN, Li X, Xu Z, Zan H, Casali P. B cell Sirt1 deacetylates histone and non-histone proteins for epigenetic modulation of AID expression and the antibody response. Sci Adv. 2020;6:eaay2793.PubMedPubMedCentralCrossRef
82.
Wang Z-L, Luo X-F, Li M-T, Xu D, Zhou S, Chen H-Z, Gao N, Chen Z, Zhang L-L, Zeng X-F. Resveratrol possesses protective effects in a pristane-induced lupus mouse model. PLoS ONE. 2014;9: e114792.PubMedPubMedCentralCrossRef
83.
84.
Wang Y, He J, Liao M, Hu M, Li W, Ouyang H, Wang X, Ye T, Zhang Y, Ouyang L. An overview of Sirtuins as potential therapeutic target: structure, function and modulators. Eur J Med Chem. 2019;161:48–77.PubMedCrossRef
85.
Qian W, Cai X, Qian Q. Sirt1 antisense long non-coding RNA attenuates pulmonary fibrosis through sirt1-mediated epithelial-mesenchymal transition. Aging (Albany NY). 2020;12:4322–36.PubMedCrossRef
86.
Li J, Liu J, Yue W, Xu K, Cai W, Cui F, Li Z, Wang W, He J. Andrographolide attenuates epithelial-mesenchymal transition induced by TGF-β1 in alveolar epithelial cells. J Cell Mol Med. 2020;24:10501–11.PubMedPubMedCentralCrossRef
87.
Yi YW, Kang HJ, Kim HJ, Kong Y, Brown ML, Bae I. Targeting mutant p53 by a SIRT1 activator YK-3-237 inhibits the proliferation of triple-negative breast cancer cells. Oncotarget. 2013;4:984–94.PubMedPubMedCentralCrossRef
88.
Schiedel M, Rumpf T, Karaman B, Lehotzky A, Oláh J, Gerhardt S, Ovádi J, Sippl W, Einsle O, Jung M. Aminothiazoles as potent and selective Sirt2 inhibitors: a structure–activity relationship study. J Med Chem. 2016;59:1599–612.PubMedCrossRef
89.
Quan Y, Xia L, Shao J, Yin S, Cheng CY, Xia W, Gao W-Q. Adjudin protects rodent cochlear hair cells against gentamicin ototoxicity via the SIRT3-ROS pathway. Sci Rep. 2015;5:8181.PubMedPubMedCentralCrossRef
90.
Sosnowska B, Mazidi M, Penson P, Gluba-Brzózka A, Rysz J, Banach M. The sirtuin family members SIRT1, SIRT3 and SIRT6: their role in vascular biology and atherogenesis. Atherosclerosis. 2017;265:275–82.PubMedCrossRef
91.
Song C, Zhao J, Fu B, Li D, Mao T, Peng W, Wu H, Zhang Y. Melatonin-mediated upregulation of Sirt3 attenuates sodium fluoride-induced hepatotoxicity by activating the MT1-PI3K/AKT-PGC-1α signaling pathway. Free Radic Biol Med. 2017;112:616–30.PubMedCrossRef
92.
Zhang M, Lin J, Wang S, Cheng Z, Hu J, Wang T, Man W, Yin T, Guo W, Gao E, Reiter RJ, Wang H, Sun D. Melatonin protects against diabetic cardiomyopathy through Mst1/Sirt3 signaling. J Pineal Res. 2017;63:e12418.CrossRef
93.
Chen Y, Qing W, Sun M, Lv L, Guo D, Jiang Y. Melatonin protects hepatocytes against bile acid-induced mitochondrial oxidative stress via the AMPK-SIRT3-SOD2 pathway. Free Radic Res. 2015;49:1275–84.PubMedCrossRef
94.
Lu J, Zhang H, Chen X, Zou Y, Li J, Wang L, Wu M, Zang J, Yu Y, Zhuang W, Xia Q, Wang J. A small molecule activator of SIRT3 promotes deacetylation and activation of manganese superoxide dismutase. Free Radic Biol Med. 2017;112:287–97.PubMedCrossRef
Metadata
Title
Sirtuins and Cellular Senescence in Patients with Idiopathic Pulmonary Fibrosis and Systemic Autoimmune Disorders
Authors
Vito D’Agnano
Domenica Francesca Mariniello
Raffaella Pagliaro
Mehrdad Savabi Far
Angela Schiattarella
Filippo Scialò
Giulia Stella
Maria Gabriella Matera
Mario Cazzola
Andrea Bianco
Fabio Perrotta
Publication date
17-04-2024
Publisher
Springer International Publishing
Published in
Drugs
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.1007/s40265-024-02021-8